Skip to main content
COSMO Pharmaceuticals N.V. logo

COSMO Pharmaceuticals N.V. — Investor Relations & Filings

Ticker · COPN ISIN · NL0011832936 LEI · 724500OX0EBQRYTVV639 SW Manufacturing
Open in API
Filings indexed 169 across all filing types
Latest filing 2023-05-26 AGM Information
Country NL Netherlands
Listing SW COPN

About COSMO Pharmaceuticals N.V.

https://www.cosmopharma.com/

COSMO Pharmaceuticals N.V. is a specialty pharmaceutical company focused on developing and commercializing products in gastroenterology, dermatology, and healthtech. The company's portfolio is built around its proprietary MMX® technology, a platform for the targeted delivery of active ingredients in the colon. Key products include GI Genius™, an AI-powered device for endoscopy; Winlevi®, a topical treatment for acne; and therapies for inflammatory bowel diseases such as Lialda®/Mezavant® and Uceris®/Cortiment®. In addition to its own product pipeline, Cosmo provides contract manufacturing services, including process assessment, technology transfer, stability testing, and market release for pharmaceutical products.

Recent filings

Filing Released Lang Actions
Aktionärinnen und Aktionäre von Cosmo Pharmaceuticals stimmen an der Generalversammlung allen Traktanden zu
AGM Information Classification · 98% confidence The document is a press release dated May 26, 2023, announcing that the shareholders of Cosmo Pharmaceuticals N.V. approved all agenda items at the General Meeting. Key items mentioned include the approval of the 2022 Annual Financial Statements, dividend distribution, discharge of the Board, and the reappointment of the auditor for 2023. The core subject is the outcome and resolutions passed during the Annual General Meeting (AGM). This directly corresponds to the 'AGM Information' category.
2023-05-26 German
Cosmo announces territory expansion agreement for Lumeblue™ (Methylene Blue MMX™) with China Medical System Holdings
M&A Activity Classification · 99% confidence The document is a press release dated March 30, 2023, announcing a territory expansion of a license agreement for Lumeblue™ with China Medical System Holdings. It details business developments, clinical trial results, and partnership updates. It is not a formal regulatory filing like a 10-K, nor is it a short announcement about a report (RPA/RNS). It contains significant business and operational news, which aligns best with a general corporate announcement or press release. Since there is no specific category for a general business/partnership press release, and it is not an Earnings Release (ER) or Interim Report (IR), the most appropriate fallback category is Regulatory Filings (RNS), as it is a formal announcement disseminated to the market via a news service (EQS News Service). However, given the content is a major business development announcement, it is often classified as a general corporate announcement. In the provided list, RNS serves as the general regulatory/miscellaneous announcement category. The document also lists an upcoming Annual General Meeting (AGM) date, but the content itself is not AGM material.
2023-03-30 English
Cosmo kündigt Gebietserweiterungs-Vereinbarung für Lumeblue™ (Methylenblau MMX™) mit China Medical System Holdings an
Regulatory Filings Classification · 100% confidence The document is a press release dated March 30, 2023, announcing a territory expansion agreement for a drug (Lumeblue™) with a partner (China Medical System Holdings). It details clinical trial results, regulatory filings (NDA submission), and provides a financial calendar. This type of announcement, which communicates significant business developments, partnerships, and clinical/regulatory milestones outside of routine financial reporting (like 10-K or ER), is best classified as a general Regulatory Filing or Announcement. Since it is not a formal financial report (10-K, IR, ER, MRQ) nor a specific announcement like a dividend (DIV) or management change (MANG), and it is a formal communication of a material event, the most appropriate general category is Regulatory Filings (RNS), as it functions as a broad regulatory disclosure.
2023-03-30 German
Cosmo reports record 2022 financial results exceeding guidance, increased dividend by 10%, confirms 2023 guidance
Earnings Release Classification · 100% confidence The document is titled 'Ad hoc announcement pursuant to Art. 53 LR' and explicitly states it reports 'full-year 2022 financial results for the year ended 31 December 2022.' It contains detailed financial highlights, income statement tables, management commentary on results, and 2023 guidance. This content strongly indicates a primary release of periodic financial performance data. While it includes an invitation to a conference call (suggesting CT) and mentions the Annual Report is available for download (suggesting RPA), the core purpose and bulk of the text is the summary of the annual financial results, which aligns best with an Earnings Release (ER) for annual results, or potentially an Interim/Quarterly Report (IR) if the company uses this code for annual summaries as well, though ER is typically for the initial release of results. Given the comprehensive nature of the financial summary and the announcement date (March 23, 2023, for FY2022), it functions as the primary announcement of the annual results, fitting the 'Earnings Release' definition better than the comprehensive '10-K' which is the formal filing. Since it is the initial release of the full-year results, ER is the most appropriate code. FY 2022
2023-03-23 English
Cosmo meldet Rekordergebnisse für 2022, welche die Prognosen übertreffen, erhöht Dividende um 10%, bestätigt Prognose für 2023
Earnings Release Classification · 100% confidence The document is titled 'Ad hoc-Mitteilung gemäss Art. 53 KR' (Ad hoc announcement pursuant to Art. 53 KR) and explicitly states it announces the financial results for the fiscal year 2022 ('Cosmo gibt die Finanzergebnisse für das Geschäftsjahr 2022 bekannt'). It contains key financial highlights (Revenue, EBITDA, Net Cash Flow) and management commentary, which are characteristic of an Earnings Release (ER). However, it also includes detailed financial tables comparing 2022 to 2021, guidance for 2023, and mentions that the full 'Jahresbericht 2022' (Annual Report 2022) is available for download. Since this document is a formal press release summarizing the annual performance and providing forward-looking guidance, it fits the definition of an Earnings Release (ER) better than a comprehensive Annual Report (10-K) or a simple Report Publication Announcement (RPA). The length (15,073 chars) suggests it is more than just a brief announcement. It is not a 10-K because it is presented as an 'Ad hoc-Mitteilung' and directs users to download the full 'Jahresbericht'. It is not an RPA because it contains substantial financial data and commentary, not just a notice of publication. Therefore, ER is the most appropriate classification for this detailed results summary. FY 2022
2023-03-23 German
Cosmo Pharmaceuticals announces that Cosmo Intelligent Medical Devices – IMD Ltd, fully owned subsidiary of Cosmo Pharmaceuticals, and Medtronic to expand cooperation on GI Genius™
M&A Activity Classification · 99% confidence The document is titled 'Ad hoc announcement pursuant to Art. 53 LR' and announces an expansion of cooperation between Cosmo Intelligent Medical Devices and Medtronic regarding the GI Genius™ module. This type of announcement, which details a significant business agreement or development outside of routine financial reporting, is typically classified as a general regulatory announcement or 'Inside Information' release, especially when referencing specific listing rules (Art. 53 LR). Since it is not a formal financial report (10-K, IR, ER), a management discussion (MDA), or a specific corporate action like a dividend or share buyback, the most appropriate general category for this type of material, non-standard regulatory disclosure is 'Regulatory Filings' (RNS), which serves as a catch-all for significant, non-categorized news releases.
2023-03-22 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.